Guanine

Guanine

SCHEMBL1100665

Nc1nc2nc[nH]c2c(=O)[nH]1.c1ncc2[nH]cnc2n1

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PNP P00491 2/20 0.70
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
MAPT P10636 1/20 0.49
THRB P10828 1/20 0.49
HPGD P15428 1/20 0.49
KMT2A Q03164 1/20 0.49
HSD17B10 Q99714 1/20 0.49
GRIA1 P42261 1/20 0.44
GRIA2 P42262 1/20 0.44
GRIA3 P42263 1/20 0.44
GRIA4 P48058 1/20 0.44
XDH P47989 3/20 0.40
GDA Q9Y2T3 1/20 0.40
DPP4 P27487 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guanine SCHEMBL27594331 0.94 PNP (0.62) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL16552675 0.94 PNP (0.62) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL3820889 0.93 PNP (0.60) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL28064900 0.91 PNP (0.58) PNPALDH1A1KDM4EMEN1MAPT
8-Azaguanine SCHEMBL3953066 0.86 PNP (0.51) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL30814355 0.85 PNP (0.96) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL8008324 0.84 PNP (0.50) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL18154053 0.84 PNP (0.50) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL5260 0.84 PNP (1.00) PNPALDH1A1KDM4EMEN1MAPT
Guanine SCHEMBL1264884 0.84 PNP (1.00) PNPALDH1A1KDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023241051-A1 FLUORESCENTLY LABELED COMPOSITE SGRNA, AND PREPARATION METHOD THEREFOR AND USE THEREOF 图维生物医药科技(苏州)有限公司 2023-12-21 WO claimed
US-20240226275-A1 COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION RNAimmune, Inc. (US) 2024-07-11 US disclosed
CN-118302181-A Multigang TP53 and PAN-RAS mRNA cancer vaccine 达冕生物有限公司 2024-07-05 CN disclosed
EP-4388017-A1 COMPOSITIONS AND METHODS FOR ANTI-VIRUS CHIMERIC ANTIGEN RECEPTOR Rudd, Christopher E. (CA) 2024-06-26 EP disclosed
EP-4384214-A2 COMPOSITION AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION Rnaimmune, Inc. (US) 2024-06-19 EP disclosed
CN-118119930-A Compositions and methods for mRNA vaccines against novel coronavirus infection 达冕生物有限公司 2024-05-31 CN disclosed
US-20240156947-A1 COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS RNAimmune, Inc. (US) 2024-05-16 US disclosed
WO-2024097894-A1 COMPOSITIONS AND METHODS OF RIBONUCLEIC ACID VACCINES ENCODING NYE-SO-1 RNAimmune, Inc. (US) 2024-05-10 WO disclosed
WO-2024097259-A1 COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS RNAimmune, Inc. (US) 2024-05-10 WO disclosed
EP-4351615-A2 MULTIPLEXED TP53 AND PAN-RAS MRNA CANCER VACCINES Rnaimmune, Inc. (US) 2024-04-17 EP disclosed
EP-0472498-A1 Monoclonal antibodies to leptosphaeria CIBA-GEIGY AG (CH) 1992-02-26 EP disclosed
EP-0465415-A2 Monoclonal antibodies to mycosphaerella species CIBA-GEIGY AG (CH) 1992-01-08 EP disclosed
US-4879217-A MONOCLONAL ANTIBODIES FOR IMMUNOASSAY AGRI-DIAGNOSTICS ASSOCIATES (US) 1989-11-07 US disclosed
US-4845197-A IMMUNOLOGICAL DETECTION OF FUNGAL PLANT DISEASES AGRI-DIAGNOSTICS ASSOCIATES (US) 1989-07-04 US disclosed
US-4803155-A DETECTION OF PATHOGENIC FUNGUS IN TURFGRASS, USING AN ANALYTICALLY DETECTABLE LABELLED ANTIBODY-ANTIGEN COMPLEX AGRI-DIAGNOSTICS ASSOCIATES (US) 1989-02-07 US disclosed
EP-0292719-A2 A test for rhizoctonia brown and yellow patch DNAP DIAGNOSTICS, INC. (a Delaware corporation) (US) 1988-11-30 EP disclosed
EP-0234501-A2 Monocional antibodies and methods for fungal pathogen detection DNAP DIAGNOSTICS, INC. (a Delaware corporation) (US) 1987-09-02 EP disclosed
EP-0222998-A2 Monoclonal antibodies and methods for fungal pathogen detection DNAP DIAGNOSTICS, INC. (a Delaware corporation) (US) 1987-05-27 EP disclosed
US-4564597-A Anti-Sm hybridoma RESEARCH CORPORATION (US) 1986-01-14 US disclosed
US-4246408-A Imidazo[1,2-a]-s-triazine ICN PHARMACEUTICALS (US) 1981-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240156947-A1 COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS RBM22, RNGTT, RBM25 PNP 200/4885ALDH1A1 4880/4885KDM4E 4620/4885
US-20240226275-A1 COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION RNGTT, SARS1, ACE2 PNP 241/4885ALDH1A1 4884/4885KDM4E 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.